BOSTON, MA -- July 27, 2006 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics markets, today announced that it has signed a multi-year, multi-million dollar agreement to supply the state of Texas with instruments, software and reagents to enhance the Texas newborn screening program. The technology will be used to test for metabolic disorders in the estimated 375,000 infants born in Texas each year.

Under the terms of the agreement, PerkinElmer will provide the Texas Department of State Health Services Laboratory with tandem mass spectrometry systems, as well as reagent kits and software enhancements to support the state's newborn screening program.

"We are pleased to work with the state of Texas on this important initiative, to provide its department of health with the technology to test for multiple disorders from a single sample," said Robert F. Friel, president of PerkinElmer Life and Analytical Sciences. "By utilizing this leading technology, we are able to detect potentially devastating metabolic disorders at an early stage to allow for better treatment and management options, leading to an improved quality of life."

With the addition of Texas, PerkinElmer has now signed long-term agreements for tandem mass spectrometry solutions with nine states, including Alabama, California, Florida, Kentucky, Louisiana, Missouri, Pennsylvania and South Carolina.

PerkinElmer is the world's leading supplier to newborn screening laboratories. The Company believes that every baby screened in North America today is tested with one of PerkinElmer's many products.

Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries; (2) risks related to our failure to introduce new products in a timely manner; (3) our ability to comply with financial covenants contained in our credit agreements and our debt instruments; (4) a delay in resolution of the Company's tax audits and an adverse determination with respect to the Company's tax audits by the Internal Revenue Service or other taxing authorities; (5) cyclical downturns continuing to affect several of the industries into which we sell our products; (6) our ability to adjust our operations to address unexpected changes; (7) our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business; (8) the loss of any of our licenses that may require us to stop selling products or lose competitive advantage; (9) competition; (10) regulatory compliance; (11) regulatory changes; (12) our failure to obtain and enforce intellectual property protection; (13) our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets; (14) other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.